Publication date: Jul 01, 2024

COVID-19 is a viral infection affecting the respiratory system, primarily. It has spread globally ever since it first appeared in China in 2019. The use of high-flow nasal oxygen (HFNO) for the treatment of COVID-19 has not been well established. The primary objectives of this study are to observe the success of HFNO in preventing escalation to mechanical ventilation (MV) and to measure the prevalence of HFNO in King Abdulaziz Medical City (KAMC). The secondary objective is to describe patients who received HFNO clinically. This is a retrospective cohort study of all polymerase chain reaction (PCR)-confirmed COVID-19 patients who require oxygen therapy in KAMC, Jeddah between March 1st, 2020, and December 31st, 2020. Any patients requiring MV on admission were excluded. 259 patients fit the inclusion criteria, and 25. 5% of those included received HFNO. The number of non-survivors is 47 (18. 1%). Mortality for HFNO, MV, and intensive care unit (ICU) are 30 (45. 5%), 31 (60. 8%), and 24 (32%), respectively. Their demographic was as follows; 160 were males, with a mean age of 60. 93+/-15. 01. Regarding the types of oxygen, low-flow nasal oxygen (LFNO) was administered to 243 out of the 259 patients, 66 received HFNO, 42 received MV, and 49 received other modes of ventilation. Additionally, 43. 9% received HFNO escalated to MV. Patients who did not receive HFNO or MV were 178 (68. 7%) in total. The use of HFNO in COVID-19 patients could show better outcomes than MV in addition to preventing the use of MV. Larger studies are required to determine the efficacy of HFNO in COVID-19 patients.

Semantics

Original Article